Advertisement

Topics

The Medicines Company announces positive top-line data for PCSK9 inhibitor

09:53 EDT 19 Oct 2016 | Cardiovascular Business

After 90 days, patients who received an investigational proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor known as PCSK9i had significant and durable reductions in low-density lipoprotein (LDL) cholesterol, according to an interim analysis of a phase 1 study.

Original Article: The Medicines Company announces positive top-line data for PCSK9 inhibitor

NEXT ARTICLE

More From BioPortfolio on "The Medicines Company announces positive top-line data for PCSK9 inhibitor"

Quick Search
Advertisement